,
Saturday, 15 May 2021 01:36 GMT

Asia-Pacific Acute Myeloid Leukemia Treatment Market Size, Development Status, Growth Analysis , Share, News, Demand, Top Manufacturers and Forecasts


(MENAFN - Comserve) Shibuya-ku, Tokyo, Japan, Japan, May 05, 2021, 04:41 /Comserve / -- The report analyze market size, share, growth, trends, segmentation, top key players, strategies, demand, statistics, competitive landscape and forecast.

There has been an increasing trend in the AML cases seen in the Asian region that has increased the number of clinical trials into new therapies for leukemia patients. In Japan, approximately 4,500 patients are being diagnosed with AML every year, according to a 2018 report by Astellas Pharma Inc. Moreover, the survey has also reported that the prevalence of AML is higher in the geriatric population. As the geriatric population is increasing in percentage, this disease may cause an economic burden on the overall population.

According to a report by Elton B. Stephens Co.(EBSCO) 2017, the prevalence (5-year period) of AML in lower-income Asia-Pacific countries and high-income Asia- Pacific countries was 4 per 100,000 and 7 per 100,000, respectively. Asia-pacific comprises of countries that are not only economically developing, but their population is also increasing every year at a significant rate. Hence as the population of these countries increases, the risk of incidence of AML is also high.

Thus owing to the increase in the prevalence of AML in the Asia-Pacific region, this market is expected to grow during the forecast period.

Key Market Trends

Click Here to Download Sample Report >> 

Chemotherapy is thus Expected to Hold the Largest Market Share During the Forecast Period

Chemotherapy is the main treatment for most people with acute myeloid leukemia (AML). Induction is the first phase of treatment. It is short and intensive, typically lasting about a week. The goal is to clear the blood of leukemia cells (blasts) and to reduce the number of blasts in the bone marrow to normal. Consolidation is chemo given after the patient has recovered from induction. It is meant to kill the small number of leukemia cells that are still around but can’t be seen (because there are so few of them). For consolidation, chemo is given in cycles, with each period of treatment followed by a rest period to allow the body time to recover. A third phase called maintenance (or post-consolidation) involves giving a low dose of chemo for months or years after the consolidation is finished. This is often used to treat acute promyelocytic leukemia (APL), but it is rarely used for other types of AML.

Drugs like Daunomycin, Idarubicin, and Mitoxantrone have been dominated the market, and new research discoveries are expected to further help the growth of this segment. Moreover, the prevalence of leukaemia is increasing and AML is one of the most common causes of death in leukaemia. Hence the incidence of AML is also expected to increcase in Asia. This will increase the demand of AML treatment, helping the market growth.

Competitive Landscape

The market for acute myeloid leukemia treatment in Asia-Pacific is moderately competitive and comprises of the global players majorly. Some of the key players in this market are Novartis AG, Pfizer Inc., Teva Pharmaceuticals, AbbVie Inc., among others. With the rising focus of pharmaceutical companies to provide better therapeutics for cancer, it is believed that more companies will be penetrating the market in the near future.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Request For Full Report >>  

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
4.3 Market Restraints
4.3.1 Complications Related to Chemotherapy
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Therapy
5.1.1 Chemotherapy
5.1.1.1 Anthracycline Drugs
5.1.1.2 Alkylating Agents
5.1.1.3 Anti-metabolites
5.1.1.4 Other Chemotherapies
5.1.2 Targeted Therapy
5.1.3 Stem Cell Transplant
5.1.4 Other Therapies
5.2 Geography
5.2.1 Asia Pacific
5.2.1.1 China
5.2.1.2 Japan
5.2.1.3 India
5.2.1.4 Australia
5.2.1.5 South Korea
5.2.1.6 Rest of Asia-Pacific

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astellas Pharma Inc.
6.1.2 AbbVie Inc.
6.1.3 Celgene Corporation
6.1.4 Daiichi Sankyo Company Limited
6.1.5 Novartis AG
6.1.6 Pfizer Inc.
6.1.7 Teva Pharmaceutical Industries Ltd
6.1.8 Mylan NV
6.1.9 Sun Pharmaceutical Industries Ltd
6.1.10 Fresenius SE & Co. KGaA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

 

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.


For more information, please contact:

Hina Miyazu

Shibuya Data Count
Email:
Tel: + 81 3 45720790

MENAFN05052021004694010674ID1102031437


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Authors_Square_PromoteArticle_Ink2019